Scholarlink

Purpose <p>Selective Internal Radiotherapy (SIRT) is an established treatment option for hepatocellular carcinoma (HCC). However, a major complication is radioembolization-induced liver disease (REILD).</p> Methods <p>This retrospective study, analyzed patients treated with SIRT for HCC to identify clinical factors associated with REILD and to predict treatment response. Machine learning (ML) methods were applied to two distinct cohorts to determine predictors of toxicity and response.</p> Results <p>Among 138 patients analyzed for REILD, ML identified bilirubin as a key predictor. A refined threshold of 26.5 µmol/L (1.55&#xa0;mg/dL) was associated with toxicity risk. In the response cohort (136 patients), predictive performance was limited, nevertheless tumor dose appeared as the most frequent feature selected by the models.</p> Conclusions <p>Bilirubin was confirmed as a critical factor for REILD prediction with the identification of a new threshold that may improve patient risk stratification. While tumor dose appears as the main predictor of treatment outcome, robust response models require additional features.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Itzel Rivera,
  • Heloïse Bourien,
  • Ewan Morel-Corlu,
  • Alexandre Peinoit,
  • Samuel Le Sourd,
  • Yan Rolland,
  • Etienne Garin,
  • Oscar Acosta,
  • Julien Edeline

摘要

Purpose

Selective Internal Radiotherapy (SIRT) is an established treatment option for hepatocellular carcinoma (HCC). However, a major complication is radioembolization-induced liver disease (REILD).

Methods

This retrospective study, analyzed patients treated with SIRT for HCC to identify clinical factors associated with REILD and to predict treatment response. Machine learning (ML) methods were applied to two distinct cohorts to determine predictors of toxicity and response.

Results

Among 138 patients analyzed for REILD, ML identified bilirubin as a key predictor. A refined threshold of 26.5 µmol/L (1.55 mg/dL) was associated with toxicity risk. In the response cohort (136 patients), predictive performance was limited, nevertheless tumor dose appeared as the most frequent feature selected by the models.

Conclusions

Bilirubin was confirmed as a critical factor for REILD prediction with the identification of a new threshold that may improve patient risk stratification. While tumor dose appears as the main predictor of treatment outcome, robust response models require additional features.